- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The Clinical Oncology Next Generation Sequencing (NGS) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Clinical Oncology Next Generation Sequencing (NGS) market size is estimated to be worth US$ 725.1 million in 2021 and is forecast to a readjusted size of USD 1422.5 million by 2028 with a CAGR of 10.1% during review period. Academic & Clinical Research accounting for % of the Clinical Oncology Next Generation Sequencing (NGS) global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While NGS Pre-Sequencing segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Clinical Oncology Next Generation Sequencing (NGS) include Illumina, Roche, Agilent Technologies, Knome, and Genomatix Software, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Clinical Oncology Next Generation Sequencing (NGS) market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
NGS Pre-Sequencing
Sequencing
NGS Data Analysis
Primary, Secondary & Tertiary Data Analysis
Market segment by Application, can be divided into
Academic & Clinical Research
Hospitals & Clinics
Pharma & Biotech Entities
Market segment by players, this report covers
Illumina
Roche
Agilent Technologies
Knome
Genomatix Software
GATC Biotech
Oxford Nanopore Technologies
Macrogen
Life Technologies
DNASTAR
Exosome Diagnostics
Biomatters
CLC Bio
BGI
Qiagen
Perkin Elmer
Pacific Bioscience
Partek
GnuBIO
Foundation Medicine
Paradigm
Caris Life Sciences
Myriad Genetics
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Clinical Oncology Next Generation Sequencing (NGS) product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Clinical Oncology Next Generation Sequencing (NGS), with revenue, gross margin and global market share of Clinical Oncology Next Generation Sequencing (NGS) from 2019 to 2022.
Chapter 3, the Clinical Oncology Next Generation Sequencing (NGS) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Clinical Oncology Next Generation Sequencing (NGS) market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Clinical Oncology Next Generation Sequencing (NGS) research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Clinical Oncology Next Generation Sequencing (NGS)
1.2 Classification of Clinical Oncology Next Generation Sequencing (NGS) by Type
1.2.1 Overview: Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Type in 2021
1.2.3 NGS Pre-Sequencing
1.2.4 Sequencing
1.2.5 NGS Data Analysis
1.2.6 Primary, Secondary & Tertiary Data Analysis
1.3 Global Clinical Oncology Next Generation Sequencing (NGS) Market by Application
1.3.1 Overview: Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Academic & Clinical Research
1.3.3 Hospitals & Clinics
1.3.4 Pharma & Biotech Entities
1.4 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size & Forecast
1.5 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast by Region
1.5.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region, (2017-2022)
1.5.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size and Prospect (2017-2028)
1.5.4 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size and Prospect (2017-2028)
1.5.6 South America Clinical Oncology Next Generation Sequencing (NGS) Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Clinical Oncology Next Generation Sequencing (NGS) Market Drivers
1.6.2 Clinical Oncology Next Generation Sequencing (NGS) Market Restraints
1.6.3 Clinical Oncology Next Generation Sequencing (NGS) Trends Analysis
2 Company Profiles
2.1 Illumina
2.1.1 Illumina Details
2.1.2 Illumina Major Business
2.1.3 Illumina Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.1.4 Illumina Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Illumina Recent Developments and Future Plans
2.2 Roche
2.2.1 Roche Details
2.2.2 Roche Major Business
2.2.3 Roche Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.2.4 Roche Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Roche Recent Developments and Future Plans
2.3 Agilent Technologies
2.3.1 Agilent Technologies Details
2.3.2 Agilent Technologies Major Business
2.3.3 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.3.4 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Agilent Technologies Recent Developments and Future Plans
2.4 Knome
2.4.1 Knome Details
2.4.2 Knome Major Business
2.4.3 Knome Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.4.4 Knome Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Knome Recent Developments and Future Plans
2.5 Genomatix Software
2.5.1 Genomatix Software Details
2.5.2 Genomatix Software Major Business
2.5.3 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.5.4 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Genomatix Software Recent Developments and Future Plans
2.6 GATC Biotech
2.6.1 GATC Biotech Details
2.6.2 GATC Biotech Major Business
2.6.3 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.6.4 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 GATC Biotech Recent Developments and Future Plans
2.7 Oxford Nanopore Technologies
2.7.1 Oxford Nanopore Technologies Details
2.7.2 Oxford Nanopore Technologies Major Business
2.7.3 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.7.4 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Oxford Nanopore Technologies Recent Developments and Future Plans
2.8 Macrogen
2.8.1 Macrogen Details
2.8.2 Macrogen Major Business
2.8.3 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.8.4 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Macrogen Recent Developments and Future Plans
2.9 Life Technologies
2.9.1 Life Technologies Details
2.9.2 Life Technologies Major Business
2.9.3 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.9.4 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Life Technologies Recent Developments and Future Plans
2.10 DNASTAR
2.10.1 DNASTAR Details
2.10.2 DNASTAR Major Business
2.10.3 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.10.4 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 DNASTAR Recent Developments and Future Plans
2.11 Exosome Diagnostics
2.11.1 Exosome Diagnostics Details
2.11.2 Exosome Diagnostics Major Business
2.11.3 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.11.4 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Exosome Diagnostics Recent Developments and Future Plans
2.12 Biomatters
2.12.1 Biomatters Details
2.12.2 Biomatters Major Business
2.12.3 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.12.4 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Biomatters Recent Developments and Future Plans
2.13 CLC Bio
2.13.1 CLC Bio Details
2.13.2 CLC Bio Major Business
2.13.3 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.13.4 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 CLC Bio Recent Developments and Future Plans
2.14 BGI
2.14.1 BGI Details
2.14.2 BGI Major Business
2.14.3 BGI Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.14.4 BGI Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 BGI Recent Developments and Future Plans
2.15 Qiagen
2.15.1 Qiagen Details
2.15.2 Qiagen Major Business
2.15.3 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.15.4 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15.5 Qiagen Recent Developments and Future Plans
2.16 Perkin Elmer
2.16.1 Perkin Elmer Details
2.16.2 Perkin Elmer Major Business
2.16.3 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.16.4 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16.5 Perkin Elmer Recent Developments and Future Plans
2.17 Pacific Bioscience
2.17.1 Pacific Bioscience Details
2.17.2 Pacific Bioscience Major Business
2.17.3 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.17.4 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17.5 Pacific Bioscience Recent Developments and Future Plans
2.18 Partek
2.18.1 Partek Details
2.18.2 Partek Major Business
2.18.3 Partek Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.18.4 Partek Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18.5 Partek Recent Developments and Future Plans
2.19 GnuBIO
2.19.1 GnuBIO Details
2.19.2 GnuBIO Major Business
2.19.3 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.19.4 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19.5 GnuBIO Recent Developments and Future Plans
2.20 Foundation Medicine
2.20.1 Foundation Medicine Details
2.20.2 Foundation Medicine Major Business
2.20.3 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.20.4 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.20.5 Foundation Medicine Recent Developments and Future Plans
2.21 Paradigm
2.21.1 Paradigm Details
2.21.2 Paradigm Major Business
2.21.3 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.21.4 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.21.5 Paradigm Recent Developments and Future Plans
2.22 Caris Life Sciences
2.22.1 Caris Life Sciences Details
2.22.2 Caris Life Sciences Major Business
2.22.3 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.22.4 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.22.5 Caris Life Sciences Recent Developments and Future Plans
2.23 Myriad Genetics
2.23.1 Myriad Genetics Details
2.23.2 Myriad Genetics Major Business
2.23.3 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.23.4 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.23.5 Myriad Genetics Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Clinical Oncology Next Generation Sequencing (NGS) Players Market Share in 2021
3.2.2 Top 10 Clinical Oncology Next Generation Sequencing (NGS) Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Clinical Oncology Next Generation Sequencing (NGS) Players Head Office, Products and Services Provided
3.4 Clinical Oncology Next Generation Sequencing (NGS) Mergers & Acquisitions
3.5 Clinical Oncology Next Generation Sequencing (NGS) New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Market Share by Type (2017-2022)
4.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Application (2017-2022)
5.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Type (2017-2028)
6.2 North America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Application (2017-2028)
6.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country
6.3.1 North America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Country (2017-2028)
6.3.2 United States Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2017-2028)
6.3.3 Canada Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2017-2028)
6.3.4 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue by Type (2017-2028)
7.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue by Application (2017-2028)
7.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country
7.3.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue by Country (2017-2028)
7.3.2 Germany Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2017-2028)
7.3.3 France Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2017-2028)
7.3.5 Russia Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2017-2028)
7.3.6 Italy Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue by Type (2017-2028)
8.2 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue by Application (2017-2028)
8.3 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region
8.3.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue by Region (2017-2028)
8.3.2 China Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2017-2028)
8.3.3 Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2017-2028)
8.3.4 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2017-2028)
8.3.5 India Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2017-2028)
8.3.7 Australia Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Type (2017-2028)
9.2 South America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Application (2017-2028)
9.3 South America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country
9.3.1 South America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Country (2017-2028)
9.3.2 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2017-2028)
9.3.3 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue by Type (2017-2028)
10.2 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue by Application (2017-2028)
10.3 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country
10.3.1 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue by Country (2017-2028)
10.3.2 Turkey Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2017-2028)
10.3.4 UAE Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million) by Region (2017-2022)
Table 5. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Region (2023-2028)
Table 6. Illumina Corporate Information, Head Office, and Major Competitors
Table 7. Illumina Major Business
Table 8. Illumina Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 9. Illumina Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Roche Corporate Information, Head Office, and Major Competitors
Table 11. Roche Major Business
Table 12. Roche Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 13. Roche Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Agilent Technologies Corporate Information, Head Office, and Major Competitors
Table 15. Agilent Technologies Major Business
Table 16. Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 17. Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Knome Corporate Information, Head Office, and Major Competitors
Table 19. Knome Major Business
Table 20. Knome Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 21. Knome Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Genomatix Software Corporate Information, Head Office, and Major Competitors
Table 23. Genomatix Software Major Business
Table 24. Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 25. Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. GATC Biotech Corporate Information, Head Office, and Major Competitors
Table 27. GATC Biotech Major Business
Table 28. GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 29. GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Oxford Nanopore Technologies Corporate Information, Head Office, and Major Competitors
Table 31. Oxford Nanopore Technologies Major Business
Table 32. Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 33. Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Macrogen Corporate Information, Head Office, and Major Competitors
Table 35. Macrogen Major Business
Table 36. Macrogen Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 37. Macrogen Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Life Technologies Corporate Information, Head Office, and Major Competitors
Table 39. Life Technologies Major Business
Table 40. Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 41. Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. DNASTAR Corporate Information, Head Office, and Major Competitors
Table 43. DNASTAR Major Business
Table 44. DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 45. DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Exosome Diagnostics Corporate Information, Head Office, and Major Competitors
Table 47. Exosome Diagnostics Major Business
Table 48. Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 49. Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Biomatters Corporate Information, Head Office, and Major Competitors
Table 51. Biomatters Major Business
Table 52. Biomatters Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 53. Biomatters Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. CLC Bio Corporate Information, Head Office, and Major Competitors
Table 55. CLC Bio Major Business
Table 56. CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 57. CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. BGI Corporate Information, Head Office, and Major Competitors
Table 59. BGI Major Business
Table 60. BGI Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 61. BGI Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. Qiagen Corporate Information, Head Office, and Major Competitors
Table 63. Qiagen Major Business
Table 64. Qiagen Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 65. Qiagen Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 66. Perkin Elmer Corporate Information, Head Office, and Major Competitors
Table 67. Perkin Elmer Major Business
Table 68. Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 69. Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 70. Pacific Bioscience Corporate Information, Head Office, and Major Competitors
Table 71. Pacific Bioscience Major Business
Table 72. Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 73. Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 74. Partek Corporate Information, Head Office, and Major Competitors
Table 75. Partek Major Business
Table 76. Partek Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 77. Partek Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 78. GnuBIO Corporate Information, Head Office, and Major Competitors
Table 79. GnuBIO Major Business
Table 80. GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 81. GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 82. Foundation Medicine Corporate Information, Head Office, and Major Competitors
Table 83. Foundation Medicine Major Business
Table 84. Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 85. Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 86. Paradigm Corporate Information, Head Office, and Major Competitors
Table 87. Paradigm Major Business
Table 88. Paradigm Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 89. Paradigm Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 90. Caris Life Sciences Corporate Information, Head Office, and Major Competitors
Table 91. Caris Life Sciences Major Business
Table 92. Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 93. Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 94. Myriad Genetics Corporate Information, Head Office, and Major Competitors
Table 95. Myriad Genetics Major Business
Table 96. Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 97. Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 98. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 99. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 100. Breakdown of Clinical Oncology Next Generation Sequencing (NGS) by Company Type (Tier 1, Tier 2 and Tier 3)
Table 101. Clinical Oncology Next Generation Sequencing (NGS) Players Head Office, Products and Services Provided
Table 102. Clinical Oncology Next Generation Sequencing (NGS) Mergers & Acquisitions in the Past Five Years
Table 103. Clinical Oncology Next Generation Sequencing (NGS) New Entrants and Expansion Plans
Table 104. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million) by Type (2017-2022)
Table 105. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Type (2017-2022)
Table 106. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Forecast by Type (2023-2028)
Table 107. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue by Application (2017-2022)
Table 108. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Forecast by Application (2023-2028)
Table 109. North America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Type (2017-2022) & (USD Million)
Table 110. North America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Type (2023-2028) & (USD Million)
Table 111. North America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Application (2017-2022) & (USD Million)
Table 112. North America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Application (2023-2028) & (USD Million)
Table 113. North America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Country (2017-2022) & (USD Million)
Table 114. North America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Country (2023-2028) & (USD Million)
Table 115. Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue by Type (2017-2022) & (USD Million)
Table 116. Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue by Type (2023-2028) & (USD Million)
Table 117. Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue by Application (2017-2022) & (USD Million)
Table 118. Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue by Application (2023-2028) & (USD Million)
Table 119. Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue by Country (2017-2022) & (USD Million)
Table 120. Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue by Country (2023-2028) & (USD Million)
Table 121. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue by Type (2017-2022) & (USD Million)
Table 122. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue by Type (2023-2028) & (USD Million)
Table 123. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue by Application (2017-2022) & (USD Million)
Table 124. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue by Application (2023-2028) & (USD Million)
Table 125. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue by Region (2017-2022) & (USD Million)
Table 126. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue by Region (2023-2028) & (USD Million)
Table 127. South America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Type (2017-2022) & (USD Million)
Table 128. South America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Type (2023-2028) & (USD Million)
Table 129. South America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Application (2017-2022) & (USD Million)
Table 130. South America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Application (2023-2028) & (USD Million)
Table 131. South America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Country (2017-2022) & (USD Million)
Table 132. South America Clinical Oncology Next Generation Sequencing (NGS) Revenue by Country (2023-2028) & (USD Million)
Table 133. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue by Type (2017-2022) & (USD Million)
Table 134. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue by Type (2023-2028) & (USD Million)
Table 135. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue by Application (2017-2022) & (USD Million)
Table 136. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue by Application (2023-2028) & (USD Million)
Table 137. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue by Country (2017-2022) & (USD Million)
Table 138. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Clinical Oncology Next Generation Sequencing (NGS) Picture
Figure 2. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Type in 2021
Figure 3. NGS Pre-Sequencing
Figure 4. Sequencing
Figure 5. NGS Data Analysis
Figure 6. Primary, Secondary & Tertiary Data Analysis
Figure 7. Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Application in 2021
Figure 8. Academic & Clinical Research Picture
Figure 9. Hospitals & Clinics Picture
Figure 10. Pharma & Biotech Entities Picture
Figure 11. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 12. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Forecast (2017-2028) & (USD Million)
Figure 13. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Region (2017-2028)
Figure 14. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Region in 2021
Figure 15. North America Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. South America Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Clinical Oncology Next Generation Sequencing (NGS) Market Drivers
Figure 21. Clinical Oncology Next Generation Sequencing (NGS) Market Restraints
Figure 22. Clinical Oncology Next Generation Sequencing (NGS) Market Trends
Figure 23. Illumina Recent Developments and Future Plans
Figure 24. Roche Recent Developments and Future Plans
Figure 25. Agilent Technologies Recent Developments and Future Plans
Figure 26. Knome Recent Developments and Future Plans
Figure 27. Genomatix Software Recent Developments and Future Plans
Figure 28. GATC Biotech Recent Developments and Future Plans
Figure 29. Oxford Nanopore Technologies Recent Developments and Future Plans
Figure 30. Macrogen Recent Developments and Future Plans
Figure 31. Life Technologies Recent Developments and Future Plans
Figure 32. DNASTAR Recent Developments and Future Plans
Figure 33. Exosome Diagnostics Recent Developments and Future Plans
Figure 34. Biomatters Recent Developments and Future Plans
Figure 35. CLC Bio Recent Developments and Future Plans
Figure 36. BGI Recent Developments and Future Plans
Figure 37. Qiagen Recent Developments and Future Plans
Figure 38. Perkin Elmer Recent Developments and Future Plans
Figure 39. Pacific Bioscience Recent Developments and Future Plans
Figure 40. Partek Recent Developments and Future Plans
Figure 41. GnuBIO Recent Developments and Future Plans
Figure 42. Foundation Medicine Recent Developments and Future Plans
Figure 43. Paradigm Recent Developments and Future Plans
Figure 44. Caris Life Sciences Recent Developments and Future Plans
Figure 45. Myriad Genetics Recent Developments and Future Plans
Figure 46. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Players in 2021
Figure 47. Clinical Oncology Next Generation Sequencing (NGS) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 48. Global Top 3 Players Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share in 2021
Figure 49. Global Top 10 Players Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share in 2021
Figure 50. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 51. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Type in 2021
Figure 52. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share Forecast by Type (2023-2028)
Figure 53. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Application in 2021
Figure 54. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share Forecast by Application (2023-2028)
Figure 55. North America Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Type (2017-2028)
Figure 56. North America Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Application (2017-2028)
Figure 57. North America Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Country (2017-2028)
Figure 58. United States Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Canada Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Mexico Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Europe Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Type (2017-2028)
Figure 62. Europe Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Application (2017-2028)
Figure 63. Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Country (2017-2028)
Figure 64. Germany Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. France Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Russia Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Italy Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Type (2017-2028)
Figure 70. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Application (2017-2028)
Figure 71. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Region (2017-2028)
Figure 72. China Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Japan Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South Korea Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. India Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Australia Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. South America Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Type (2017-2028)
Figure 79. South America Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Application (2017-2028)
Figure 80. South America Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Country (2017-2028)
Figure 81. Brazil Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 82. Argentina Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 83. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Type (2017-2028)
Figure 84. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Application (2017-2028)
Figure 85. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Country (2017-2028)
Figure 86. Turkey Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 87. Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 88. UAE Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 89. Methodology
Figure 90. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
